Trial reportClinical and experimental immunology2014
VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis.
Trial report in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Genetic polymorphisms as multi-biomarkers in severe acute respiratory syndrome (SARS) by coronavirus infection: A systematic review of candidate gene association studies.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Pooled it
- Effect of CD14 polymorphisms on the risk of cardiovascular disease: evidence from a meta-analysis.Lipids in health and disease · 2019Pooled it
- Monocytic Cell Adhesion to Oxidised Ligands: Relevance to Cardiovascular Disease.Biomedicines · 2022Article
- Polyene Phosphatidylcholine Interacting with TLR-2 Prevents the Synovial Inflammation via Inactivation of MAPK and NF-κB Pathways.Inflammation · 2022Article
- Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice.Scientific reports · 2022Article
- NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation.International journal of inflammation · 2022Article
- Recognition of Oxidized Lipids by Macrophages and Its Role in Atherosclerosis Development.Biomedicines · 2021Review
- Treatment with lecinoxoids attenuates focal and segmental glomerulosclerosis development in nephrectomized rats.Basic & clinical pharmacology & toxicology · 2019Article
- Association betweenNeuropsychiatric disease and treatment · 2019Article
- Direct Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease.Frontiers in immunology · 2019Review
- The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease.Frontiers in medicine · 2018Review
- The effect of oxidized phospholipids on phenotypic polarization and function of macrophages.Free radical biology & medicine · 2017Review
- Identification of Motile Sperm Domain-Containing Protein 2 as Regulator of Human Monocyte Migration.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Context-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation.Trends in endocrinology and metabolism: TEM · 2017Review
- Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis.Digestive diseases and sciences · 2016Article
- CD14 gene-159C/T polymorphism and coronary artery disease: a meta-analysis involving 4467 subjects.International journal of clinical and experimental medicine · 2015Article
- A lack of association between theBiomedical reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is an inflammatory disease of the vascular wall. Activated monocytes and dendritic cells (DC) in the intima layer of the vasculature promote atherogenesis. Toll-like receptor (TLR)-2 and TLR-4, which are predominantly expressed on these cells and mediate their activation, are essential for atherosclerosis development. In this study we demonstrate that VB-201, an oxidized phospholipid (Ox-PL) small molecule, inhibits TLR signalling restricted to TLR-2 and TLR-4 in human and mouse monocytes and DC. Mechanistically, we show that VB-201 binds directly to TLR-2 and CD14, the TLR-4 co-receptor, to impair downstream cues and cytokine production. In a rabbit model, oral administration of VB-201 constrained atherosclerosis progression. This effect was not due to reduced cholesterol abundance, as hyperlipidaemia was sustained. We suggest that VB-201 may counter inflammation where TLR-2 and/or CD14 complicity is essential, and is therefore beneficial for the treatment of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.